Continued improvement in survival of acute myeloid leukemia patients: an application of the loss in expectation of life-Reference-Cited by-同舟云学术

Continued improvement in survival of acute myeloid leukemia patients: an application of the loss in expectation of life

Published:2016-02 Issue:2 Volume:6 Page:e390-e390
ISSN:2044-5385
Container-title:Blood Cancer Journal
language:en
Short-container-title:Blood Cancer Journal

Author:

Bower H,Andersson T M-L,Björkholm M,Dickman P W,Lambert P C,Derolf Å R

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology

Link

http://www.nature.com/articles/bcj20163.pdf

Reference35 articles.

1. National Cancer Institute. Surveillance Epidemiology and End Results. Available from http://seer.cancer.gov/faststats/selections.php?#Output (accessed 17 June 2014)..

2. Juliusson G, Antunovic P, Derolf A, Lehmann S, Mollgard L, Stockelberg D et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 2009; 113: 4179–4187.

3. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453–474.

4. Burnett A, Wetzler M, Lowenberg B . Therapeutic advances in acute myeloid leukemia. J Clin Oncol 2011; 29: 487–494.

5. Maurillo L, Buccisano F, Del Principe MI, Del Poeta G, Spagnoli A, Panetta P et al. Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia. J Clin Oncol 2008; 26: 4944–4951.

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Transplant Eligible and Ineligible Elderly Patients with AML—A Genomic Approach and Next Generation Questions;Biomedicines;2024-04-29

2. Vemurafenib induces senescence in acute myeloid leukemia and myelodysplastic syndrome by activating the HIPPO signaling pathway: implications for potential targeted therapy;Biology Direct;2024-01-04

3. Pharmacoeconomic evaluation of isavuconazole, posaconazole, and voriconazole for the treatment of invasive mold diseases in hematological patients: initial therapy prior to pathogen differential diagnosis in China;Frontiers in Public Health;2023-12-19

4. Increase in the Life Expectancy of Patients with Cancer in the United States;Cancer Epidemiology, Biomarkers & Prevention;2023-12-13

5. Modulation of bone marrow and peripheral blood cytokine levels by age and clonal hematopoiesis in healthy individuals;Clinical Immunology;2023-10